In this update, we cover news about making sterile drugs, producing biological treatments, developing cell lines, and creating radiopharmaceuticals. Symbiosis, a company based in Stirling, Scotland, has increased its ability to make sterile drugs. They have successfully set up a new automated filling and packaging line called FPD 50 Flexicon. This expansion allows them to produce more high-quality sterile drugs, which are in high demand. Their new system uses advanced technology for filling vials accurately and maintaining sterility. BioGrad, a UK biotech company, plans to open a new Centre of Bio-Manufacturing Excellence in Liverpool. This facility, which follows strict quality standards, will focus on speeding up research into advanced cell and gene therapies, including treatments like CAR T-cell therapy. Construction is set to begin by the end of the year, and BioGrad hopes this center will make the North of England a leader in these advanced treatments. Abzena, a US company, has improved its platform for developing cell lines through a partnership with Revvity, a Massachusetts medical technology company. They have launched new systems for producing proteins, which can be used either independently or as part of a complete quality-assured program. Eschbach, a software developer for process industries, has introduced a new batch tracking solution for its manufacturing platform. This solution helps production, quality assurance, and quality control teams work together more efficiently by automatically collecting data from various systems. The new system is ready for validation and supports digital signatures and audits. XenoStart has expanded its partnership with Minerva Imaging to create an integrated platform for developing radiopharmaceutical drugs. This collaboration combines XenoStart’s collection of patient-derived cancer models with Minerva’s expertise in molecular imaging and radionuclide therapy. The platform aims to set a new standard in cancer research, particularly for prostate cancer.